Dow Up0.03% Nasdaq Up0.14%

AcelRx Pharmaceuticals, Inc. (ACRX)

-NasdaqGM
7.37 Up 0.04(0.60%) 10:31AM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
AcelRx Pharmaceuticals, Inc.
351 Galveston Drive
Redwood City, CA 94063
United States - Map
Phone: 650-216-3500
Fax: 650-216-6500
Website: http://www.acelrx.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Medical Appliances & Equipment
Full Time Employees:44

Business Summary 

AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain (BTP). Its principal product candidate is Zalviso, an investigational pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. The company is also developing ARX-04, a Sufentanil Single-Dose NanoTab, which has completed Phase II clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as on the battlefield, in the emergency room, or in ambulatory care facilities. In addition, its product candidate pipeline consists of ARX-02, a Sufentanil NanoTab pain management system, which has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain (BTP); and ARX-03, a Sufentanil/Triazolam NanoTab, a Phase II clinical trials completed product designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on AcelRx Pharmaceuticals, Inc.

Corporate Governance 
AcelRx Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Sep 1, 2014 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 3.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Richard A. King , 49
Chief Exec. Officer, Pres, Chief Commercial Officer and Director
760.00K0.00
Dr. Pamela P. Palmer M.D., Ph.D., 51
Co-Founder, Chief Medical Officer and Director
591.00K0.00
Mr. Anil N. Dasu , 51
Chief Engineering Officer
437.00K0.00
Mr. Timothy E. Morris CPA, 52
Chief Financial Officer
N/AN/A
Ms. Jane Wright Mitchell ,
Chief Legal Officer
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders